Get the Stockscreener App
3.23
2.71%
-0.09
After Hours:
3.20
-0.03
-0.93%
Alpha Tau Medical Ltd stock is traded at $3.23, with a volume of 62,948.
It is down -2.71% in the last 24 hours and up +1.89% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
See More
Previous Close:
$3.32
Open:
$3.23
24h Volume:
62,948
Relative Volume:
0.77
Market Cap:
$226.43M
Revenue:
-
Net Income/Loss:
$-29.64M
P/E Ratio:
-7.5116
EPS:
-0.43
Net Cash Flow:
$-39.43M
1W Performance:
-15.00%
1M Performance:
+1.89%
6M Performance:
+60.70%
1Y Performance:
+0.31%
1-Day Range:
$3.20
$3.30
1-Week Range:
$3.14
$3.95
52-Week Range:
$1.75
$4.3866
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
3.23 | 226.43M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Increases By 7.1% - MarketBeat
Alpha Tau Medical Gets FDA Approval to Expand DaRT Study in Pancreatic Cancer - Marketscreener.com
Alpha Tau Medical Ltd. Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT®? to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease - Marketscreener.com
Alpha Tau Gains FDA Approval to Expand Pancreatic Cancer Trial - TipRanks
Alpha Tau Announces FDA Approval of IDE Supplement to - GlobeNewswire
Major Clinical Trial Expansion: Alpha Tau Doubles Down on Revolutionary Pancreatic Cancer Treatment - StockTitan
Alpha Emitter Market Projected To Witness Massive Growth, - openPR
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day - GlobeNewswire
Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials - TipRanks
Alpha Tau shares interim data across multiple clinical trials at R&D Update Day - TipRanks
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials -January 27, 2025 at 09:02 am EST - Marketscreener.com
Alpha Tau's Cancer Therapy Shows Breakthrough Results in Multiple Clinical Trials - StockTitan
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Still a Buy? - Defense World
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Rises By 7.1% - MarketBeat
Takeout news crowns JPM’s winning stocks - BioCentury
DRTS Stock Touches 52-Week High at $3.43 Amid Sector Growth - Investing.com
DRTS Stock Touches 52-Week High at $3.43 Amid Sector Growth By Investing.com - Investing.com South Africa
US Penny Stocks To Consider In January 2025 - Simply Wall St
Alpha Tau Medical (NASDAQ:DRTSW) Stock Price Up 14.3% – Should You Buy? - Defense World
Alpha Tau to Present Groundbreaking Cancer Therapy Data at ASCO Symposium - TipRanks
Alpha Tau Announces Upcoming Presentation of New Data at - GlobeNewswire
Alpha Tau Medical to Unveil Groundbreaking Cancer Therapy Data at ASCO GI Symposium - StockTitan
Alpha Tau Medical Ltd. Announces Board Changes - Marketscreener.com
Comparing Integra LifeSciences (NASDAQ:IART) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Stock Price Up 1% – Should You Buy? - Defense World
Alpha Tau Medical Announces Board Leadership Changes Amid Strategic Expansion - TipRanks
Alpha Tau Medical Ltd. Announces Key Shareholder Decisions at Annual Meeting - TipRanks
Alpha Tau Announces Appointment of Maya Netser to its Board - GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor - Quantisnow
Alpha Tau Medical (NASDAQ:DRTS) Trading Up 1%Should You Buy? - MarketBeat
Alpha Emitter Market Set to Witness Steady Growth through (2024-2031) - WhaTech
Alpha Tau to Present at J.P. Morgan Healthcare Conference - TipRanks
DRTSAlpha Tau Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Alpha Tau Medical to Present Cancer Therapy Breakthroughs at J.P. Morgan Healthcare Conference - StockTitan
Alpha Tau to Showcase Innovations at Oncology Symposium - TipRanks
Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium - The Manila Times
Alpha Tau Medical : to Participate in Ladenburg’s Oncology Innovators & Investors Symposium Form 6 K - Marketscreener.com
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium - Marketscreener.com
Alpha Tau Medical to Present Alpha DaRT Cancer Therapy at Ladenburg Oncology Symposium - StockTitan
3 Promising Penny Stocks In The US With Market Caps Under $400M - Simply Wall St
Nyxoah (NASDAQ:NYXH) vs. Alpha Tau Medical (NASDAQ:DRTS) Head to Head Contrast - Defense World
Alpha Tau Medical Reports Q3 2024 Financial Results - TipRanks
HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Piper Sandler reaffirms OW rating on Alpha Tau Medical shares as 'multiple milestones' line up - Investing.com South Africa
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau Medical Advances in Cancer Treatment Technology - TipRanks
Alpha Tau Medical Advances Cancer Treatment Pipeline, Reports $68.4M Cash Position | DRTS Stock News - StockTitan
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):